US 10040769
HDAC inhibitors for the treatment of diabetic peripheral neuropathy
granted A61KA61K31/164A61K31/337
Quick answer
US patent 10040769 (HDAC inhibitors for the treatment of diabetic peripheral neuropathy) held by Regenacy Pharmaceuticals, Inc. expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/164, A61K31/337, A61K31/495, A61K31/505